Benzopyran

About: Benzopyran is a research topic. Over the lifetime, 1889 publications have been published within this topic receiving 15235 citations.

Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor

Abstract: The present invention relates to compounds having pharmacological activity towards the sigma (s) receptor, and more particularly to spiro[benzopyran] or spiro[benzofuran] derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.

Benzopyran kind compound and its preparation method

Abstract: The present invention relates to a benzopyran compound and its preparation method. Said preparation method includes the following steps: making phenol compound and alpha, beta-unsaturated ketone or beta, gamma-unsaturated ketene ester compound undergo the process of reflux reaction for 1-3 days in organic acid, their material-adding ratio is 1:2, after the reaction is completed, trifluoroacetic acid can be distilled out and reused, the residue can be dissolved in organic solvent of dichloromethane, washing by using saturated sodium hydrogen carbonate aqueous solution, drying by using drying agent of anhydrous sodium sulfate, filtering, desolventizing and column chromatography so as to obtain the invented product benzopyran compound.

Synthesis and Selective Coronary Vasodilatory Activity of 3,4-Dihydro- 2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol Derivatives: Novel Potassium Channel Openers.

Abstract: A variety of compounds having a benzopyran such as levcromakalim generally exhibit potent antihypertensive activity. During extensive investigations aimed toward identifying K+ channel openers having selective coronary vasodilation without potent hypotensive and tachycardiac effects, we synthesized a series of 3,4-dihydro-2H-1-benzopyran-3-ol derivatives modified at positions 2, 4, and 6 in the benzopyran ring. Initially, compounds having two methoxymethyl groups at position 2 were found to show a selective effect on coronary blood flow (CoBF) relative to mean arterial pressure (MAP) in anesthetized dogs. To find more potent vasodilators, various benzopyran derivatives modified at position 4 were synthesized and structure-activity relationships were examined by evaluation of the extent and duration of the increase in CoBF in anesthetized dogs. As a result, compounds having a (1,6-dihydro-6-oxopyridazin-3-yl)amino group at position 4, in addition to the two methoxymethyl groups at position 2, were found to be more potent and to have an improved duration of action. Among these compounds, JTV-506, (-)-(3S,4R)-6-cyano-3,4-dihydro-4-[(1,6-dihydro-1-methyl-6-oxopyridaz in-3-yl)amino]-2,2-bis(methoxymethyl)-2H-1-benzopyran-3-ol, exhibited good selectivity for its effect. Administration of this compound (0.03 mg/kg, p.o.) elicited an increase of CoBF without a change of systemic blood pressure and heart rate (HR) in conscious dogs. Further evaluation was performed with respect to (i) the selectivity of its action on the coronary artery versus the aorta and (ii) its effects on MAP, HR, and electrocardiographic ST elevation. As a result, JTV-506 was selected as a potent and selective coronary vasodilator with various pharmacological features favoring clinical development.